Table 3 Toxic and adverse effects in the patients in the two study groups
From: Preliminary investigation of intraperitoneal raltitrexed in patients with gastric cancer
Parameter | Raltitrexed group (RT) nā=ā48 | Normal saline group (NS) nā=ā43 | P value |
|---|---|---|---|
Hematologic toxicity | Ā | Ā | Ā |
RBC (10 12 /L) | Ā | Ā | Ā |
Preoperative | 3.68āĀ±ā0.22 | 3.76āĀ±ā0.14 | >0.05 |
Postoperative | 3.49āĀ±ā0.21 | 3.56āĀ±ā0.24 | >0.05 |
WBC (10 9 /L) | Ā | Ā | Ā |
Preoperative | 4.73āĀ±ā0.46 | 4.45āĀ±ā0.54 | >0.05 |
Postoperative | 6.29āĀ±ā0.63 | 6.70āĀ±ā0.52 | >0.05 |
Platelet count (10 9 /L) | Ā | Ā | Ā |
Preoperative | 183.09āĀ±ā27.19 | 178.22āĀ±ā28.24 | >0.05 |
Postoperative | 196.15āĀ±ā25.28 | 192.36āĀ±ā23.75 | >0.05 |
Renal toxicity BUN (mmol/L) | Ā | Ā | Ā |
Preoperative | 4.38āĀ±ā0.72 | 4.46āĀ±ā0.75 | >0.05 |
Postoperative | 4.87āĀ±ā1.04 | 4.68āĀ±ā0.84 | >0.05 |
Renal toxicity Creatinine (Ī¼mol/L) | Ā | Ā | Ā |
Preoperative | 76.24āĀ±ā7.67 | 73.46āĀ±ā6.95 | >0.05 |
Postoperative | 78.37āĀ±ā7.44 | 74.68āĀ±ā7.14 | >0.05 |
Hepatotoxicity (U/L) | Ā | Ā | Ā |
ALT | Ā | Ā | Ā |
Preoperative | 21.36āĀ±ā2.78 | 19.92āĀ±ā2.84 | >0.05 |
Postoperative | 24.35āĀ±ā3.02 | 22.01āĀ±ā2.65 | >0.05 |
LDH (mmol/L) | Ā | Ā | Ā |
Preoperative | 186.46āĀ±ā27.19 | 192.34āĀ±ā32.45 | >0.05 |
Postoperative | 191.24āĀ±ā26.76 | 190.56āĀ±ā30.12 | >0.05 |